Clinical Observation of Integrated Chinese Medicine With Western Medicine for the Reduction of Chemotherapy-induced Hematologic Toxicity

NCT05442177 | Completed

• 1 other identifier: REC104-12
• Study Type: observational
• Target: 35
• Locations: 0 countries
• Sites: N/A

Brief Summary

We conducted an observational study to investigate the effectiveness and safety of Integrated Chinese Medicine With Western Medicine for bone marrow suppression induced by chemotherapy in patients with cancer. The TCM constitution and pulse diagnosis was also observed in the study.

Conditions

Myelosuppression

Keywords

Traditional Chinese Medicine; radial pulse assessment; sphygmography; pulse diagnosis; myelosuppression; cancer

Outcome Measures

Primary Outcomes (1)

• Chemotherapy-induced Hematologic Toxicity

  the blood cell count before and after chemotherapy was collected for measurement of severity of myelosuppression

  one month

Interventions

Chemotherapy and Integrated Chinese Medicine With Western Medicine for cancer treatment PROCEDURE

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with cancer under chemotherapy and Integrated Chinese Medicine With Western Medicine.

You may qualify if:

• Patients with cancer diagnosed through pathological histology
• Patients with cancer under chemotherapy and Integrated Chinese Medicine With Western Medicine
• Patients with an Eastern Cooperative Oncology Group Performance score of 0-2
• Patients having normal liver and kidney functions and electrocardiography and eligible for chemotherapy with normal bone marrow hematopoietic function
• Patients who were voluntarily involved in this study

You may not qualify if:

• Patients who could not cooperate with pulse diagnosis
• Patients with underlying diseases such as chronic obstructive pulmonary disease, cardiac failure, chronic renal failure, cirrhosis, etc.
• Patients with severe infection
• Patients with severe cachexia

Sponsors & Collaborators

• Taichung Tzu Chi Hospital: lead

MeSH Terms

Conditions

Neoplasms

Interventions

Drug Therapy

Intervention Hierarchy (Ancestors)

Therapeutics

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Chinese medicine department

Study Record Dates

• First Submitted: June 28, 2022
• First Posted: July 1, 2022
• Study Start: July 1, 2015
• Primary Completion: June 30, 2016
• Study Completion: June 30, 2016
• Last Updated: July 1, 2022

Record last verified: 2022-06